Effects of adjunct treatment with intravenous immunoglobulins on the course of severe COVID-19 : results from a retrospective cohort study
OBJECTIVES: To evaluate the effect of adjunct treatment with Octagam, an intravenous immunoglobulin (IVIG) product, on clinical outcomes and biomarkers in critically ill COVID-19 patients.
METHODS: Data from a single center was analyzed retrospectively. Patients had received preliminary standard intensive care (SIC) according to a local treatment algorithm, either alone or along with IVIG 5% at 30 g/day for 5 days. The two groups were compared regarding baseline characteristics, survival and changes in inflammation markers. Imbalance in baseline APACHE II scores was addressed by propensity score matching. Otherwise, Kaplan-Meier and multiple logistic regression models were used.
RESULTS: Out of 93 patients, 51 had received IVIG and 42 had not. About 75% of patients were male and both groups had comparable body mass index and AB0 blood type distribution. IVIG-treated patients were younger (mean 65 ± 15 versus 71 ± 15 years, p = .066) and had slightly lower baseline disease scores (APACHE II: 20.6 versus 22.4, p = .281; SOFA: 5.0 versus 7.0, p = .006). Overall survival was 61% in the SIC + IVIG and 38% in the SIC only group (odds ratio: 2.2, 95% confidence interval: 0.9-5.4, p = .091 after controlling for baseline imbalances). IVIG significantly prolonged median survival time (68 versus 18 days, p = .014) and significantly reduced plasma levels of C-reactive protein (median change from baseline -71.5 versus -0.3 mg/L, p = .049).
CONCLUSION: Clinically relevant benefits through adjunct IVIG treatment in COVID-19 need to be confirmed in a randomized, controlled trial.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:37 |
|---|---|
| Enthalten in: |
Current medical research and opinion - 37(2021), 4 vom: 08. Apr., Seite 543-548 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Esen, Figen [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Completed 06.04.2021 Date Revised 07.12.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/03007995.2020.1856058 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM318033453 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM318033453 | ||
| 003 | DE-627 | ||
| 005 | 20231225164518.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/03007995.2020.1856058 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1060.xml |
| 035 | |a (DE-627)NLM318033453 | ||
| 035 | |a (NLM)33236646 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Esen, Figen |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Effects of adjunct treatment with intravenous immunoglobulins on the course of severe COVID-19 |b results from a retrospective cohort study |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 06.04.2021 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a OBJECTIVES: To evaluate the effect of adjunct treatment with Octagam, an intravenous immunoglobulin (IVIG) product, on clinical outcomes and biomarkers in critically ill COVID-19 patients | ||
| 520 | |a METHODS: Data from a single center was analyzed retrospectively. Patients had received preliminary standard intensive care (SIC) according to a local treatment algorithm, either alone or along with IVIG 5% at 30 g/day for 5 days. The two groups were compared regarding baseline characteristics, survival and changes in inflammation markers. Imbalance in baseline APACHE II scores was addressed by propensity score matching. Otherwise, Kaplan-Meier and multiple logistic regression models were used | ||
| 520 | |a RESULTS: Out of 93 patients, 51 had received IVIG and 42 had not. About 75% of patients were male and both groups had comparable body mass index and AB0 blood type distribution. IVIG-treated patients were younger (mean 65 ± 15 versus 71 ± 15 years, p = .066) and had slightly lower baseline disease scores (APACHE II: 20.6 versus 22.4, p = .281; SOFA: 5.0 versus 7.0, p = .006). Overall survival was 61% in the SIC + IVIG and 38% in the SIC only group (odds ratio: 2.2, 95% confidence interval: 0.9-5.4, p = .091 after controlling for baseline imbalances). IVIG significantly prolonged median survival time (68 versus 18 days, p = .014) and significantly reduced plasma levels of C-reactive protein (median change from baseline -71.5 versus -0.3 mg/L, p = .049) | ||
| 520 | |a CONCLUSION: Clinically relevant benefits through adjunct IVIG treatment in COVID-19 need to be confirmed in a randomized, controlled trial | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a SARS-CoV 2 | |
| 650 | 4 | |a critical care | |
| 650 | 4 | |a inflammation | |
| 650 | 4 | |a intravenous immunoglobulins | |
| 650 | 7 | |a Immunoglobulins, Intravenous |2 NLM | |
| 650 | 7 | |a Octagam |2 NLM | |
| 700 | 1 | |a Özcan, Perihan E |e verfasserin |4 aut | |
| 700 | 1 | |a Orhun, Günseli |e verfasserin |4 aut | |
| 700 | 1 | |a Polat, Özlem |e verfasserin |4 aut | |
| 700 | 1 | |a Anaklı, İlkay |e verfasserin |4 aut | |
| 700 | 1 | |a Alay, Gülçin |e verfasserin |4 aut | |
| 700 | 1 | |a Tuna, Verda |e verfasserin |4 aut | |
| 700 | 1 | |a Çeliksoy, Emre |e verfasserin |4 aut | |
| 700 | 1 | |a Kılıç, Mehmet |e verfasserin |4 aut | |
| 700 | 1 | |a Mercan, Mutlu |e verfasserin |4 aut | |
| 700 | 1 | |a Tukek, Tufan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current medical research and opinion |d 1972 |g 37(2021), 4 vom: 08. Apr., Seite 543-548 |w (DE-627)NLM000081019 |x 1473-4877 |7 nnns |
| 773 | 1 | 8 | |g volume:37 |g year:2021 |g number:4 |g day:08 |g month:04 |g pages:543-548 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/03007995.2020.1856058 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 37 |j 2021 |e 4 |b 08 |c 04 |h 543-548 | ||